Clinical Trials Logo

Clinical Trial Summary

This study design is A Randomized, Double-blind, Multi-center, Phase II Optimal Dose-finding Study to Determine the Safety and Efficacy of Meditoxin® in Subjects in Benign Masseteric Hypertrophy.


Clinical Trial Description

Subjects who voluntarily signed the informed consent and are judged to be eligible for this study will be intramuscularly injected with the study drug or the placebo to find appropreate dose for the treatment of Benign Masseteric Hypertrophy. Thereafter, follow-up visits will be made and efficacy and safety assessment will be conducted. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02292472
Study type Interventional
Source Medy-Tox
Contact
Status Completed
Phase Phase 2
Start date October 6, 2014
Completion date August 24, 2015